Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Heath

Showing results (141-150 of 248) with videos related to

Pageof 25
Sort By:
Oncotarget|November 20, 2018
Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progressionAmro Aboukameel, Irfana Muqbil, Erkan Baloglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate CancerUlka N Vaishampayan, Izabela Podgorski, Lance K Heilbrun, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2016
A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumorsJustine Yang Bruce, Patricia M LoRusso, Priscila H Goncalves, et al.
Clinical Pharmacology and Therapeutics|October 29, 2010
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumorsE I Heath, E G Chiorean, C J Sweeney, et al.
The Medical Journal of Australia|October 6, 2001
Adult-to-adult living donor liver transplantation for fulminant hepatic failureA K House, G P Jeffrey, K A Edyvane, et al.
Cancer Medicine|April 1, 2024
Characterization and impact of non-canonical WNT signaling on outcomes of urothelial carcinomaMargaret Meagher, Harris Krause, Andrew Elliott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2022
Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate CancerUlka N Vaishampayan, Archana Thakur, Wei Chen, et al.
JCO Oncology Practice|December 3, 2019
Unpacking Trial Offers and Low Accrual Rates: A Qualitative Analysis of Clinic Visits With Physicians and Patients Potentially Eligible for a Prostate Cancer Clinical TrialLauren M Hamel, David W Dougherty, Terrance L Albrecht, et al.
Cancer Chemotherapy and Pharmacology|January 25, 2013
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumorsElisabeth I Heath, Jeffrey Infante, Lionel D Lewis, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2001
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumorsE I Heath, S O'Reilly, R Humphrey, et al.
Pageof 25

Showing results (141-150 of 248) with videos related to

Sort By:
Pageof 25
Oncotarget|November 20, 2018
Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progressionAmro Aboukameel, Irfana Muqbil, Erkan Baloglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate CancerUlka N Vaishampayan, Izabela Podgorski, Lance K Heilbrun, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2016
A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumorsJustine Yang Bruce, Patricia M LoRusso, Priscila H Goncalves, et al.
Clinical Pharmacology and Therapeutics|October 29, 2010
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumorsE I Heath, E G Chiorean, C J Sweeney, et al.
The Medical Journal of Australia|October 6, 2001
Adult-to-adult living donor liver transplantation for fulminant hepatic failureA K House, G P Jeffrey, K A Edyvane, et al.
Cancer Medicine|April 1, 2024
Characterization and impact of non-canonical WNT signaling on outcomes of urothelial carcinomaMargaret Meagher, Harris Krause, Andrew Elliott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2022
Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate CancerUlka N Vaishampayan, Archana Thakur, Wei Chen, et al.
JCO Oncology Practice|December 3, 2019
Unpacking Trial Offers and Low Accrual Rates: A Qualitative Analysis of Clinic Visits With Physicians and Patients Potentially Eligible for a Prostate Cancer Clinical TrialLauren M Hamel, David W Dougherty, Terrance L Albrecht, et al.
Cancer Chemotherapy and Pharmacology|January 25, 2013
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumorsElisabeth I Heath, Jeffrey Infante, Lionel D Lewis, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2001
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumorsE I Heath, S O'Reilly, R Humphrey, et al.
Pageof 25